Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Pfizer Inc.
PFE
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $136.1B
$24.34
▲ +1.93%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$23.11 - $28.75
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 5.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
6 reasons
- Extensive patent portfolio protecting blockbuster drugs with multi-year exclusivity periods
- Global manufacturing and distribution infrastructure enabling rapid market access across 180+ countries
- Strong R&D capabilities and strategic partnerships with leading biotech firms accelerating pipeline innovation
- Diversified product portfolio reducing dependence on single therapeutic areas or drugs
- Established relationships with healthcare providers, governments, and regulatory agencies built over 170+ years
- Scale advantages in clinical trials, regulatory navigation, and commercialization reducing time-to-market
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Expanding vaccine portfolio addressing pneumococcal, meningococcal, and emerging infectious diseases
Value
Undervalued - trading well below Large Cap Pharma peers
Momentum
Weak
-15.7% over 3m
Quality
Excellent
Excellent business quality
Dividend
High yield
7.20% yield
Smart-money signal
Who's buying PFE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 27, 2026
MAY 5, 2026
Reported EPS of $0.75 vs $0.72 consensus (+3.9% surprise). Revenue of $14.5B vs $13.8B expected (+4.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+3.9%
Next: Apr 27, 2026
Revenue trend · last 8Q
—
—
+22%
-8%
+10%
-6%
-1%
+5%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$13.3B
$17.7B
$17.8B
$13.7B
$14.7B
$16.7B
$17.6B
$14.5B
Margins · last 8Q
Gross
67.3%
Operating
27.9%
Profit
18.6%
Wall Street consensus
11 analysts · 45% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
45%
Hold
55%
Sell
0%
Median Price Target
$26.50
▲ +8.9% vs $24.34
Latest: BMO Capital · Jun 23, 2026
2 analysts covering